Who
Michael Morrissey
Director
Company insider
Files Form 4 as: Director, Vera Therapeutics; President and CEO, Exelixis.
In numbers
- Trades disclosed
- 451
- Buys
- 1
- Sells
- 49
- Bought
- $88K
- Sold
- $58.2M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 8 Dec 2006
- Last trade
- 21 May 2026
- Last filed
- 26 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 May 2026filed 26 May 2026 | VERA Vera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,084 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | VERA Vera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,084 at $0.00 | filing |
| 18 May 2026filed 19 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code G | —124,047 at $0.00 | filing |
| 18 May 2026filed 19 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code G | —124,047 at $0.00 | filing |
| 18 May 2026filed 19 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code G | —124,047 at $0.00 | filing |
| 18 May 2026filed 19 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code G | —124,047 at $0.00 | filing |
| 15 May 2026filed 19 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code F | $6.6M128,497 at $51.10 | filing |
| 15 May 2026filed 19 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code F | $6.6M128,497 at $51.10 | filing |
| 6 May 2026filed 8 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code G | —109,676 at $0.00 | filing |
| 6 May 2026filed 8 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code G | —109,676 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —160,437 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —160,437 at $0.00 | filing |
| 24 Feb 2026filed 2 Mar 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code G | —100,278 at $0.00 | filing |
| 24 Feb 2026filed 2 Mar 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code G | —100,278 at $0.00 | filing |
| 18 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code G | —125,094 at $0.00 | filing |
| 18 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code G | —125,094 at $0.00 | filing |
| 18 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code G | —125,094 at $0.00 | filing |
| 18 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code G | —125,094 at $0.00 | filing |
| 17 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code G | —250,736 at $0.00 | filing |
| 17 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code G | —250,736 at $0.00 | filing |
News
Citizens Jmp Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) StockEXEL · tickerreport.com · 21 Oct 2026Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law FirmEXEL · prnewswire.com · 13 Oct 2026
0 headlines in the last 90 days name Michael Morrissey; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.